Personal information

Other IDs

Scopus Author ID: 56913350700

Activities

Collapse all

Employment (4)

National Research Centre: Giza, EG

2022-12 to present | Postdoctoral researcher (Microbial Biotechnology )
Employment
Source: Self-asserted source
Sara Kishta

Paul Ehrlich Institut: Langen, DE

2018-04-01 to 2022-11-30 | Scientist (Virology)
Employment
Source: Self-asserted source
Sara Kishta

Goethe University Frankfurt: Frankfurt am Main, Hessen, DE

2018-09-01 to 2022-09-30 | Ph.D (FB15)
Employment
Source: Self-asserted source
Sara Kishta

National Research Centre: Cairo, EG

2009-01-01 to 2018-01-01 | Researcher (Microbial Biotechnology)
Employment
Source: Self-asserted source
Sara Kishta

Education and qualifications (3)

Goethe University Frankfurt: Frankfurt am Main, Hessen, DE

2018-09-01 to 2022-09-30 | Ph.D (FB15)
Education
Source: Self-asserted source
Sara Kishta

National Research Centre: Giza, EG

2011-01 to 2015-04 | Master (Biochemistry)
Education
Source: Self-asserted source
Sara Kishta

Cairo University Faculty of Science: Cairo, EG

2004-05 to 2007-05 | Bs.c (Biochemistry)
Education
Source: Self-asserted source
Sara Kishta

Professional activities (3)

Albert Schweizer Schule : Langen, Hesse, DE

Arabic teacher to german students
Service
Source: Self-asserted source
Sara Kishta

Shandong Academy of Medical Science: Jinan, CN

2014 to 2016 | Invited Speaker
Invited position
Source: Self-asserted source
Sara Kishta

Koç University: Turkey, Istanbul, TR

2014 (School of Medicine)
Distinction
Source: Self-asserted source
Sara Kishta

Funding (3)

GERLS

Source: Self-asserted source
Sara Kishta

MSHER

2017-04 to 2022-09 | Grant
Ministry of Higher Education and Scientific Research (Cairo, EG)
URL: https://www.idaea.csic.es/medspring/location/ministry-higher-education-and-scientific-research-mhesr
Source: Self-asserted source
Sara Kishta

Researcher

Salary award
National Research Centre (Egypt, EG)
Source: Self-asserted source
Sara Kishta

Works (4)

The non-structural proteins NS3 and NS5A of Hepatitis C Virus (HCV) are degraded by two host proteolysis systems

2023-08-17 | Preprint
DOI: 10.1101/2023.08.16.553615
Contributors: Sara Mohamed; Joerg Soppa
Source: Self-asserted source
Sara Kishta

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals

Biomedicines
2020-06-25 | Journal article
DOI: 10.3390/biomedicines8060175
Contributors: Sara Kishta; Ashraf Tabll; Tea Omanovic Kolaric; Robert Smolic; Martina Smolic
Source: check_circle
Crossref

Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents

F1000Research
2017-01-25 | Journal article
DOI: 10.12688/f1000research.7970.3
Part of ISSN: 2046-1402
Source: Self-asserted source
Sara Kishta

Alteration of the total nuclear DNA ploidy in different histopathological liver tissues negative and positive for HCV RNA

Clinical Laboratory
2015 | Journal article
DOI: 10.7754/Clin.Lab.2015.141249
EID:

2-s2.0-84944750798
Contributors: Tabll, A.A.; Kishta, S.S.; Farrag, A.R.H.; El Din, N.G.B.; Mohamed, M.S.; El Abd, Y.S.; El Esawy, B.H.; Kishta, S.A.; Dawood, R.M.; Ismail, A. et al.
Source: Self-asserted source
Sara Kishta via Scopus - Elsevier
How many people are using ORCID?